Tri-modal management of primary small cell carcinoma of the pancreas (SCCP): a rare neuroendocrine carcinoma (NEC)

BMC Gastroenterology

Safa Elzein¹  Gregory P. Botta²  Fei Bao³  Gabriel Schnickel⁴  Andrew M. Lowy⁴  Ray Lin⁵ 

[1] Department of Internal Medicine, Scripps Clinic/Green Hospital, 10666 N. Torrey Pines Road, 92037, La Jolla, CA, USA;Department of Medicine, Division of Hematology/Oncology, Moores Cancer Center, University of California San Diego, 3855 Health Sciences Road, 92037, La Jolla, CA, USA;Department of Pathology, Scripps Clinic/Green Hospital, 10666 N. Torrey Pines Road, 92037, La Jolla, CA, USA;Division of Surgical Oncology, Department of Surgery, Moores Cancer Center, University of California San Diego, 3855 Health Sciences Road, 92037, La Jolla, CA, USA;Scripps Health Radiation Oncology, 10666 N. Torrey Pines Road, 92037, La Jolla, CA, USA;

关键词: Small cell;    Carcinoma;    Pancreas;    Neuroendocrine carcinoma;   

DOI  :  10.1186/s12876-021-01901-7

来源: Springer

【 摘 要 】

BackgroundPrimary small cell carcinoma of the pancreas (SCCP) is a rare malignant neuroendocrine carcinoma (NEC). Typically, it presents with lymphovascular invasion as well as metastasis at the time of diagnosis which portends a dismal prognosis. Treatment is typically based on therapy used for other aggressive NECs such as small cell lung cancer. Although multimodal surgery, radiation and chemotherapy may improve prognosis, the outcome generally remains poor.Case presentationHere we present a primary SCCP managed with neoadjuvant multi-agent chemotherapy combined with radiotherapy and surgeryConclusionsMulti-disciplinary therapy resulted in an ongoing 28 + month radiographic complete response and overall survival.

【 授权许可】

CC BY